<DOC>
	<DOCNO>NCT01821781</DOCNO>
	<brief_summary>This study hypothesize reduce intensity immunosuppressive preparative regimen establish engraftment donor hematopoietic cell acceptable early delay toxicity patient immune function disorder . A regimen maximize host immune suppression expect reduce graft rejection optimize donor cell engraftment .</brief_summary>
	<brief_title>Immune Disorder HSCT Protocol</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Granulomatous Disease , Chronic</mesh_term>
	<mesh_term>Severe Combined Immunodeficiency</mesh_term>
	<mesh_term>DiGeorge Syndrome</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
	<mesh_term>Autoimmune Lymphoproliferative Syndrome</mesh_term>
	<mesh_term>Chediak-Higashi Syndrome</mesh_term>
	<mesh_term>Genetic Diseases , X-Linked</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>&lt; /= 21 year age Performance status &gt; /= 40 DLCO &gt; /= 40 % LVEF &gt; /=40 % LVSF &gt; /=26 % Serum creatinine &lt; 2x ULN Liver enzymes &lt; /= 5x ULN Negative pregnancy test Suitably match donor ( 6/6 match sib UCB , 8/8 match sib BM PBSC , 56/6 match unrelated UCB , 78/8 match unrelated BM , double cord ) Known diagnosis HIV I/II Pregnant breastfeed Uncontrolled invasive fungal bacterial infection within 1 month prior start alemtuzumab Uncontrolled viral infection within 1 week prior start alemtuzumab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Immune deficiency</keyword>
	<keyword>Immune disorder</keyword>
	<keyword>Immune dysregulatory</keyword>
	<keyword>Reduced Intensity</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Campath</keyword>
</DOC>